ArticleCurrent topics in microbiology and immunology2023
Epidemiology of Lassa Fever.
Article in Current topics in microbiology and immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Assessing the Potential of Sexual Transmission of Lassa Virus in a Natural Rodent Reservoir.The Journal of infectious diseases · 2025Article
- Socioeconomic and environmental predictors of lassa fever transmission in Lower Bambara Chiefdom, Kenema District, Eastern Sierra Leone.BMC public health · 2025Article
- Infusion of neutralization into Lassa vaccine design.Trends in immunology · 2025Review
- Understanding Viral Haemorrhagic Fevers: Virus Diversity, Vector Ecology, and Public Health Strategies.Pathogens (Basel, Switzerland) · 2024Review
- Spatio-temporal spread and evolution of Lassa virus in West Africa.BMC infectious diseases · 2024Article
- The Perspectives of Healthcare Professionals on the Strategies, Challenges, and Community Responses to Health System Response and Interventions Towards Lassa Fever Infections and Mortality in Sierra Leone.Risk management and healthcare policy · 2024Article
- A Lassa virus mRNA vaccine confers protection but does not require neutralizing antibody in a guinea pig model of infection.Nature communications · 2023Article
- A human monoclonal antibody combination rescues nonhuman primates from advanced disease caused by the major lineages of Lassa virus.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Temporal analysis of Lassa virus infection and transmission in experimentally infectedPNAS nexus · 2022Article
- Differential pathogenesis of closely related 2018 Nigerian outbreak clade III Lassa virus isolates.PLoS pathogens · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lassa fever (LF) is a lethal hemorrhagic disease primarily concentrated in the tropical savannah regions of Nigeria and the Mano River Union countries of Sierra Leone, Liberia, and Guinea. Endemic hotspots within these countries have had recurrent exposure to Lassa virus (LASV) via continual spillover from the host reservoir Mastomys natalensis. Increased trade and travel throughout the region have spread the virus to previously unexposed countries, including Ghana, Benin, Mali, and Côte d'Ivoire. In the absence of effective treatment or vaccines to LASV, preventative measures against Lassa fever rely heavily on reducing or eliminating rodent exposure, increasing the knowledge base surrounding the virus and disease in communities, and diminishing the stigmas faced by Lassa fever survivors.
Indexed as
Identifiers
33861373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.